|
1
|
Advanced Bladder Cancer (ABC)
Meta-analysis Collaboration: Neoadjuvant chemotherapy in invasive
bladder cancer: Update of a systematic review and meta-analysis of
individual patient data advanced bladder cancer (ABC) meta-analysis
collaboration. Eur Urol. 48:202–205; discussion 205–206. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Freiha F, Reese J and Torti FM: A
randomized trial of radical cystectomy versus radical cystectomy
plus cisplatin, vinblastine and methotrexate chemotherapy for
muscle invasive bladder cancer. J Urol. 155:495–499; discussion
499–500. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sonpavde G, Sternberg CN, Rosenberg JE,
Hahn NM, Galsky MD and Vogelzang NJ: Second-line systemic therapy
and emerging drugs for metastatic transitional-cell carcinoma of
the urothelium. Lancet Oncol. 11:861–870. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Albers P, Siener R, Härtlein M, Fallahi M,
Haeutle D, Perabo FG, Steiner G, Blatter J and Müller SC: German
TCC Study Group of the German Association of Urologic Oncology:
Gemcitabine monotherapy as second-line treatment in
cisplatin-refractory transitional cell carcinoma-prognostic factors
for response and improvement of quality of life. Onkologie.
25:47–52. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Akaza H, Naito S, Usami M, Miki T,
Miyanaga N and Taniai H: Japanese Gemcitabine Study Group: Efficacy
and safety of gemcitabine monotherapy in patients with transitional
cell carcinoma after Cisplatin-containing therapy: A Japanese
experience. Jpn J Clin Oncol. 37:201–206. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Matsushima M, Kikuchi E, Masugi Y, Akita
H, Miyajima A, Jinzaki M and Oya M: Efficacy and safety of
gemcitabine monotherapy in an elderly patient with penile
metastasis from bladder carcinoma: A case report. Int Canc Conf J.
2(4): 255–260. 2013. View Article : Google Scholar
|
|
7
|
Muto S, Abe H, Noguchi T, Sugiura SI,
Kitamura K, Isotani S, Ide H, Yamaguchi R, Kamai T and Horie S:
Maintenance monotherapy with gemcitabine after standard
platinum-based chemotherapy in patients with advanced urothelial
cancer. Int J Urol. 22:490–494. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cheng L, Montironi R, Davidson DD and
Lopez-Beltran A: Staging and reporting of urothelial carcinoma of
the urinary bladder. Mod Pathol. 22:S70–S95. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
von der Maase H, Hansen SW, Roberts JT,
Dogliotti L, Oliver T, Moore MJ and Kerbrat P: Gemcitabine and
cisplatin versus methotrexate, vinblastine, doxorubicin, and
cisplatin in advanced or metastatic bladder cancer: Results of a
large, randomized, multinational, multicenter, phase III study. J
Clin Oncol. 18:3068–3077. 2000.PubMed/NCBI
|
|
10
|
Karasek P, Skacel T, Kocakova I, Bednarik
O, Petruzelka L, Melichar B, Bustova I, Spurny V and Trason T:
Gemcitabine monotherapy in patients with locally advanced or
metastatic pancreatic cancer: A prospective observational study.
Expert Opin Pharmacother. 4:581–586. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ricci S, Antonuzzo A, Galli L, Tibaldi C,
Bertuccelli M, Pegna Lopes A, Petruzzelli S, Algeri R, Bonifazi V,
Fioretto ML, et al: Gemcitabine monotherapy in elderly patients
with advanced non-small cell lung cancer: A multicenter phase II
study. Lung Cancer. 27:75–80. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Duvic M, Talpur R, Wen S, Kurzrock R,
David CL and Apisarnthanarax N: Phase II evaluation of gemcitabine
monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma.
7:51–58. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Madan RA, Gulley JL, Fojo T and Dahut WL:
Therapeutic cancer vaccines in prostate cancer: The paradox of
improved survival without changes in time to progression.
Oncologist. 15:969–975. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hernandez-Ilizaliturri FJ and Czuczman MS:
Therapeutic options in relapsed or refractory diffuse large B-cell
lymphoma. Part 1. Current treatment approaches. Oncology (Williston
Park). 23:546–553. 2009.PubMed/NCBI
|
|
15
|
Soeda A, Morita-Hoshi Y, Makiyama H,
Morizane C, Ueno H, Ikeda M, Okusaka T, Yamagata S, Takahashi N,
Hyodo I, et al: Regular dose of gemcitabine induces an increase in
CD14+ monocytes and CD11c+ dendritic cells in patients with
advanced pancreatic cancer. Jpn J Clin Oncol. 39:797–806. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Suzuki E, Kapoor V, Jassar AS, Kaiser LR
and Albelda SM: Gemcitabine selectively eliminates splenic
Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and
enhances antitumor immune activity. Clin Cancer Res. 11:6713–6721.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nowak AK, Robinson BW and Lake RA:
Gemcitabine exerts a selective effect on the humoral immune
response implications for combination chemo-immunotherapy. Cancer
Res. 62:2353–2358. 2002.PubMed/NCBI
|
|
18
|
Bellmunt J, Théodore C, Demkov T, Komyakov
B, Sengelov L, Daugaard G and Delgado FM: Phase III trial of
vinflunine plus best supportive care compared with best supportive
care alone after a platinum-containing regimen in patients with
advanced transitional cell carcinoma of the urothelial tract. J
Clin Oncol:. 27:4454–4461. 2009. View Article : Google Scholar : PubMed/NCBI
|
